ING Groep NV Cuts Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

ING Groep NV trimmed its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 63.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 87,362 shares of the biotechnology company’s stock after selling 153,438 shares during the period. ING Groep NV’s holdings in Sarepta Therapeutics were worth $1,880,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SRPT. iSAM Funds UK Ltd purchased a new position in Sarepta Therapeutics during the third quarter valued at $25,000. Ancora Advisors LLC grew its stake in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,000 shares in the last quarter. Allworth Financial LP grew its stake in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares in the last quarter. Parallel Advisors LLC grew its stake in Sarepta Therapeutics by 165.3% during the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,256 shares in the last quarter. Finally, Larson Financial Group LLC grew its stake in Sarepta Therapeutics by 82.5% during the fourth quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 851 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on SRPT. Loop Capital set a $25.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Weiss Ratings cut shares of Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Tuesday, May 26th. Citigroup lifted their price objective on shares of Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a research note on Thursday, March 26th. Wells Fargo & Company dropped their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Finally, HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a research note on Thursday, April 16th. Eight analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have assigned a Sell rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Hold” and an average price target of $24.77.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $15.89 on Wednesday. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $40.90. The stock has a market capitalization of $1.68 billion, a P/E ratio of -16.55, a PEG ratio of 0.16 and a beta of 0.21. The firm has a fifty day simple moving average of $19.61 and a two-hundred day simple moving average of $19.81. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $2.18. The firm had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.16 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The business’s revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the business earned ($3.42) EPS. On average, analysts expect that Sarepta Therapeutics, Inc. will post 3.99 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the sale, the director owned 1,765 shares in the company, valued at approximately $30,040.30. This trade represents a 80.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.90% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.